Appointment dossier — Bladder Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Bladder Cancer
No studies or cited compounds on file for this cancer yet.
Open recruiting trials (18)
- NCT06960577 · Phase 3 — Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) (Australia)
- NCT07419295 · Phase 3 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) (United States)
- NCT06545955 · Phase 3 — A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer (United States)
- NCT05706129 · Phase 1 / Phase 2 — A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors (Australia)
- NCT06630416 · Phase 2 — Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors (United States)
- NCT05327647 · Phase 2 — A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer (Canada)
- NCT07410676 · Phase 1 / Phase 2 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors (China)
- NCT06567743 · Phase 2 — Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC (United States)
- NCT07492628 · Phase 1 — Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma (China)
- NCT05521698 · Phase 1 — A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer (United States)
- NCT03108196 — Comparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal Neobladder (China)
- NCT04979156 — LaserEn: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors (United States)
- NCT07318051 — Sample Collection for Ongoing Research and Product Evaluation Study (United States)
- NCT04970472 — Bio Clinical Collection of Urothelial Carcinoma (France)
- NCT05067101 — Comparison Capsule Sparing Cystectomy and Radical Cystoprostatectomy in Men with Bladder Cancer (China)
- NCT07327489 — Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (United States)
- NCT04235764 — En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device (United States)
- NCT07545694 — Study on the Effects of Drugs That Modulate the Endocannabinoid System on Spontaneous and Induced Contractility of the Human Detrusor Muscle (Italy)
Most-relevant first: trials that name Bladder Cancer, then broader trials you may still qualify for. 392 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Questions to ask your oncologist
- Of the open trials I found (for example NCT06960577), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?